Kiniksa Pharmaceuticals, Ltd. - Special Call Transcript

Jun 29, 2020 / 12:30PM GMT
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Kiniksa announces positive data from Phase III RHAPSODY trial conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Mark Ragosa, Head of Investor Relations of Kiniksa Pharmaceuticals. Thank you. Please go ahead, sir.

Mark Ragosa - Kiniksa Pharmaceuticals, Ltd. - Senior VP & CFO

Thanks, Gigi. Good morning, and thank you for joining Kiniksa's call to discuss data from RHAPSODY, a pivotal Phase III trial of rilonacept in recurrent pericarditis. As you probably saw, our press release crossed the wire earlier this morning. Additionally, the data we present today can be found through the Investors and Media section of our website.

Please note that we'll be making forward-looking statements today that are subject to risks and uncertainties. A review of these statements and risk factors are found on this slide as well as under the heading Risk

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot